Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin

Lancet Infect Dis. 2018 Jul;18(7):717-718. doi: 10.1016/S1473-3099(18)30340-2.

Authors

David M Whiley¹, Amy Jennison², Julie Pearson³, Monica M Lahra⁴

Affiliations

¹ UQ Centre for Clinical Research, The University of Queensland, Brisbane, QLD 4029, Australia. Electronic address: d.whiley@uq.edu.au.
² Public Health Microbiology, Forensic and Scientific Services, Queensland Department of Health, Brisbane, QLD, Australia.
³ PathWest Laboratory Medicine-WA, Royal Perth Hospital, Perth, WA, Australia.
⁴ WHO, Sydney, NSW, Australia.

PMID: 29976521
DOI: 10.1016/S1473-3099(18)30340-2

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / therapeutic use*
Azithromycin / therapeutic use*
Ceftriaxone / therapeutic use*
Drug Resistance, Bacterial / genetics*
Gonorrhea / drug therapy*
Gonorrhea / genetics*
Humans
Microbial Sensitivity Tests
Neisseria gonorrhoeae / drug effects*
Neisseria gonorrhoeae / genetics*

Substances

Anti-Bacterial Agents
Ceftriaxone
Azithromycin